Alembic Pharmaceuticals Limited · NSE:APLLTD
Alembic Pharmaceuticals — Investor Presentation (July 2016)
14 slides from Alembic Pharmaceuticals's investor presentation, July 2016
Slide 1: Alembic Pharmaceuticals Ltd Investor Presentation
Alembic Pharmaceuticals Ltd Investor Presentation July-2016
Slide 2: Contents
Contents 1. Milestones 2. Quarterly Highlights 3. Business - International - India Branded 4. Strategy 5. Financials - Annual - Latest Quarter
Slide 3: Safe Harbor Statement
Safe Harbor Statement Materials and information provided during this presentation may contain ‘forward-looking statements’. These statements are based on current expectations, forecasts and assumptions that are subject to risks and uncertainties which could cause actual outcomes and results to diffe
Slide 4: Milestones
Milestones 1907 Established by Amin family 2006 FDA approves API facilities 2007 Acquired Dabur’s Indian cardiology, GI and gynaecology brands 2008 FDA approves Formulation facility 2010 Pharmaceuticals business demerged from Alembic – APL listed. 2012 Formed a JV for NCE research Launched first NDA
Slide 5: Quarterly Highlights – Q1 FY17
Quarterly Highlights – Q1 FY 17 Financial Highlights India Branded Formulations (Rs. 2777 mn) Net Sales up 25% to Rs 7358 mn Business grew by 6% Specialty Segment grew by 16% and Acute EBITDA margins at 21% at Rs 1570 mn Segment de-grew by 10%. Net Profit up 45% to Rs 1020 mn Strengtheni
Slide 6: Business
Business Sales CAGR% Rs 15bn Rs 32bn 21% Manufacturing: 16% 25% API 9% Formulation: Baddi and Sikkim for India market 38% FDA approved Oral Solids in Vadodara Doubled capacity in 2014 53% India 12% API: 3 FDA approved facilities in Vadodara 46% Expansion in 2015 22% International 46% FY12 FY16 R&D:
Slide 7: International Formulations
International Formulations Sales (Rs bn) ANDA Filed Filings: 78 Approval: 47* 14.6 13 * Incl 4 tentative CAGR 46% 8 7 7 5.6 5.9 4 3.2 3.0 FY12 FY13 FY14 FY15 FY16 FY12 FY13 FY14 FY15 FY16 R&D Spend (Rs bn) Milestones and Update 10.9 7.0 6.7 4.8 5.1 Focus on day-1 launches 3.5 Aripiprazole R&D% U
Slide 8: India Branded
India Branded Sales (Rs bn) Marketing Organisation CAGR 14% 11.0 9.8 5000 + marketing team 8.5 Added 1000 over last two years 7.5 6.6 17 marketing divisions Added new divisions in gynaecology, cardiology , GI, urology 170 products Launch 20-25 products every year FY12 FY13 FY14 FY15 FY16 Thera
Slide 9: Therapy-wise Performance Q1 FY17
Therapy-wise Performance Q1 FY17 JUN QTR 2016 JUN QTR 2015 Therapy Market Alembic Alembic Therapy Market Alembic Alembic Therapy Growth Share Growth Growth Growth Share Growth Growth (ORG) (ORG) (ORG) (PRIM) (ORG) (ORG) (ORG) (PRIM) Cardiology 10 2.01 18 16 15 1.87 49 35 Anti Diabetic 15 1.84 42 31
Slide 10: Strategy
Strategy Competitive position Growth drivers Skills US: Rapidly expand breadth and quality of pipeline Doubled internal OSD grid, half of grid is external – injectable, dermatology and ophtahalmics High Partnerships to gain time and leverage financial resource Build manufacturing capacities rapidly,
Slide 11: Financials – 5 years
Financials – 5 years Sales (Rs bn) EBITDA (Rs bn) Margins% 32% 31.8 17% 19% 19% CAGR 21% 15% 10.1 20.7 18.7 14.7 15.3 4.0 3.6 2.2 2.5 FY12 FY13 FY14 FY15 FY16 FY12 FY13 FY14 FY15 FY16 Net Profit (Rs bn) Capital employed (Rs bn) 23% ROCE% 53% 31% 40% 30% Margins% 13% 14% 25% 11% 7.2 9% 17.8 11.9 2.8
Slide 12: Financials - Quarter
Financials - Quarter Sales (Rs bn) EBITDA (Rs bn) 25% 50% 7.4 1.6 5.9 1.0 Q1FY16 Q1FY17 Q1FY16 Q1FY17 PAT (Rs bn) Business Sales 45% 30% 1.0 42% International 0.7 49% India 41% API 20% 17% Q1FY16 Q1FY17 Q1FY16 Q1FY17
Slide 13: Latest Shareholding Pattern
Latest Shareholding Pattern % of Total Shareholding 12 Promoter & Promoter group 14 FI/FII/MF Public 74 Market capitalization INR 108 bn Total paid-up share capital 377.03mn Total number of shares O/S 188.52mn No. of shareholders >50 K Free float market INR 28 bn capitalization
Slide 14: Thank You
THANK YOU
Alembic Pharmaceuticals — Investor Presentation (July 2016) on 6ix